Patents Examined by Karl J. Puttlitz
  • Patent number: 12290571
    Abstract: Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I) or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, L, L1, L2, L3, L4, L5, L6, M, m, and p are as defined herein. Methods associated with preparation and use of such compounds is also provided.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 6, 2025
    Assignee: Sony Group Corporation
    Inventors: Tracy Matray, Hesham Sherif
  • Patent number: 12285491
    Abstract: The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: April 29, 2025
    Assignee: HANGZHOU DAC BIOTECH CO., LTD.
    Inventors: Yongxin Robert Zhao, Qingliang Yang, Yuanyuan Huang, Shun Gai, Hangbo Ye, Linyao Zhao, Chengyu Yang, Huihui Guo, Xiaomai Zhou, Hongsheng Xie, Haifeng Zhu, Yifang Xu, Qianqian Tong, Junxiang Jia, Minjun Cao, Wenjun Li, Shuihong Gao, Zhixiang Guo, Lu Bai, Chen Li, Yanlei Yang, Chunyan Wang, Zhichang Ye
  • Patent number: 12281117
    Abstract: Provided is a series of homologous small molecule immune agonists and novel bifunctional immune targeting compounds having targeting and immune activation functions, which are obtained by coupling the small molecule immune agonists to targeting drugs. The resulting immune targeting compounds are beneficial for enhancing immune activation effects, and anti-tumor and other disease fighting effects of the targeting drug. The enhanced effect is produced from a synergy of immunological anti-tumor factors (such as IFN-?) and inhibition at pathogenic targeting sites.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: April 22, 2025
    Assignee: SHENZHEN UNIVERSITY
    Inventors: Guangyi Jin, Zhulin Wang, Li Tang
  • Patent number: 12239732
    Abstract: Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
    Type: Grant
    Filed: July 25, 2022
    Date of Patent: March 4, 2025
    Assignee: DEBIOPHARM INTERNATIONAL, S.A.
    Inventors: Angela Romanelli, Rodrigo R. Ruiz-Soto, Jose Ponte, Jutta Deckert, Jan Pinkas
  • Patent number: 12234262
    Abstract: The present invention relates to a vaccinia virus recombinant A33R protein and a kit for diagnosing antibodies against orthopoxvirus containing the same, and more particularly, to a recombinant A33R protein in which the transmembrane domain of the vaccinia virus A33R protein is replaced with a peptide linker, a recombinant vector for efficiently expressing the recombinant A33R protein, a transgenic organism, a method for producing the recombinant A33R protein, a composition and kit for diagnosing antibodies against orthopoxvirus containing the recombinant A33R protein.
    Type: Grant
    Filed: December 21, 2023
    Date of Patent: February 25, 2025
    Assignee: REPUBLIC OF KOREA (DEFENSE ACQUISITION PROGRAM ADMINISTRATION)
    Inventors: Eun-Ju Sohn, Hyangju Kang, So Yun Park
  • Patent number: 12221443
    Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.
    Type: Grant
    Filed: July 7, 2022
    Date of Patent: February 11, 2025
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Nakako Mitsuhashi, Yumiko Saito
  • Patent number: 12209180
    Abstract: Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene carboxamides and protein (e.g., antibody) drug conjugates thereof.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: January 28, 2025
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Jesper A. Gromada, Viktoria Gusarova, Amy Han, Sokol Haxhinasto, Andrew J. Murphy, William Olson, Matthew Sleeman
  • Patent number: 12201693
    Abstract: The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6?-deoxy position; and (ii) an amino acid 8 with an S-deoxy position; (b) a target-binding moiety; and (c) optionally a linker linking said amatoxin and said target-binding moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate.
    Type: Grant
    Filed: February 27, 2023
    Date of Patent: January 21, 2025
    Assignee: Heidelberg Pharma Research GmbH
    Inventors: Christian Lutz, Jan Anderl, Christoph Mueller, Werner Simon, Susanne Werner-Simon, Torsten Hechler, Michael Kulke
  • Patent number: 12195552
    Abstract: The present invention provides a linker for preparing antibody-drug conjugates and antibody-drug conjugates prepared by the linker, as well as use of the antibody-drug conjugates in a medicament for treating tumor. The linker is capable of coupling simultaneously with the thiol group or amino group on the antibody or functional fragment of the antibody, especially it is capable of coupling with 2, 3 or 4 thiol groups on the antibody or functional fragment of the antibody. A coupled product is uniform and structurally stable.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: January 14, 2025
    Assignee: RemeGen Co., Ltd.
    Inventors: Changjiang Huang, Hui Ye, Hu Chen, Xiuzhi Zhan, Nan Shen, Wenting Luo, Qiaohua Hou, Jianmin Fang
  • Patent number: 12194106
    Abstract: Provided are antibodies and fragments thereof having binding specificity to the liver receptor homolog 1 (LIV-1. SLC39A6 or ZIP6) protein as well as their derivatives and uses.
    Type: Grant
    Filed: May 6, 2024
    Date of Patent: January 14, 2025
    Assignee: LANOVA MEDICINES LIMITED
    Inventors: Runsheng Li, Wentao Huang, Ying Qin Zang, Zhifang Liu, Yifan Li
  • Patent number: 12194107
    Abstract: The present invention relates to an antibody comprising a GlcNAc-S(A)x substituent, wherein S(A)x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc-S(A)x substituent is bonded to the antibody via C1 of the N-acetylglucosamine of said GlcNAc-S(A)x substituent, and wherein said N-acetylglucosamine is optionally fucosylated. The invention also relates to an antibody-conjugate, in particular to an antibody-conjugate according to the Formula (20) or (20b), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N-acetylglucosamine is optionally fucosylated (b is 0 or 1). The invention further relates to a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament.
    Type: Grant
    Filed: July 6, 2020
    Date of Patent: January 14, 2025
    Assignee: Synaffix B.V.
    Inventors: Floris Louis Van Delft, Remon Van Geel, Maria Antonia Wijdeven
  • Patent number: 12186310
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.
    Type: Grant
    Filed: March 3, 2023
    Date of Patent: January 7, 2025
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Takeshi Masuda, Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Hideki Miyazaki, Yuji Kasuya, Koji Morita, Yuki Abe, Yusuke Ogitani
  • Patent number: 12186404
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target (X) R and their use in the treatment of cancer.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: January 7, 2025
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
    Inventors: Mark L. McLaughlin, David L. Morse
  • Patent number: 12187810
    Abstract: The present disclosure provides antibody-drug conjugate structures, which include a cleavable linker that links the antibody to the drug and has a first enzymatically cleavable moiety and a second enzymatically cleavable moiety which includes a glycoside selected from a galactoside, a glucoside, a mannoside, a fucoside, O-GlcNAc, and O-GalNAc. The disclosure also encompasses compounds and methods for production of such conjugates, as well as methods of using the conjugates.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: January 7, 2025
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Stepan Chuprakov, Ayodele O. Ogunkoya
  • Patent number: 12178881
    Abstract: Duocarmycin-based antibody-drug conjugates can be readily separated from non-conjugated duocarmycin linker-drug in a composition that contains a solvent system of water and acetonitrile and that has 30% to 60% acetonitrile.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: December 31, 2024
    Assignee: Byondis B.V.
    Inventor: Carolus Johannes Edgar Van Den Hoef
  • Patent number: 12171840
    Abstract: The present invention discloses an antibody drug conjugate that targets MSLN. The present invention also disclosed a method of making the antibody drug conjugate (ADC). The present invention further discloses a novel MSLN antibody or a functional fragment thereof comprising engineered heavy and light chains.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: December 24, 2024
    Assignee: RemeGen, Ltd.
    Inventors: Jianmin Fang, Changjiang Huang, Jing Jiang, Hui Ye, Shenjun Li, Qiaoyu Xu, Wenting Luo, Mingxue Wang
  • Patent number: 12168060
    Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-B7-H3 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind B7-H3, as well as methods of making and using these anti-B7-H3 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: December 17, 2024
    Assignees: IntoCell, Inc., Y-Biologics Inc.
    Inventors: Taekyo Park, Sunyoung Kim, Suho Park, Doohwan Jung, Donghoon Seo, Sangkwang Lee, Sanghyeon Yun, Jihyeon Ha, Hyang Sook Lee, Okku Park, Beomseok Seo, Sena Kim, Minah Seol, Jina Song, Sung Ho Woo, Jongun Cho, Jaeho Lee, Hyun Mi Lee, Jae Eun Park, Youngja Song, Eunjin Lee, Hyun Ju Lee, Eun-Young Shim, Yunjung Ko, Minju Lee, Young woo Park, Yosup Rew
  • Patent number: 12163966
    Abstract: A method is provided, comprising feeding a cat a foodstuff comprising a protein to fat ratio of 1:0.27 to 1:0.63 on a gram:gram as fed or dry matter basis, and measuring the level of glucose-dependent insulinotropic polypeptide (GIP) in a blood sample from the cat before and after feeding the foodstuff. A reduction in GIP levels and/or maintaining low levels of GIP post-prandially is indicative of a foodstuff useful in preventing accumulation of and/or reducing body fat in a cat and therefore controlling the body weight of a cat.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: December 10, 2024
    Assignee: Mars, Incorporated
    Inventors: Janet Alexander, Penelope Morris, Adrian Hewson-Hughes
  • Patent number: 12157768
    Abstract: Antibodies and antibody fragments that specifically bind to LILRB2 are disclosed. Also provided herein are compositions comprising antibodies and antibody fragments that specifically bind to LILRB2 and methods of use thereof. Also provided are related chimeric antigen receptors (CARs) and cells comprising same (e.g., T cells, natural killer cells, or macrophages), and uses of the CARs and cells in targeting tumors and killing them, asthma treatment, or in targeting and removing infected cells (e.g., to treat infections or infectious diseases), or in suppressing immune system cells, as involved in autoimmune disease or transplant rejection.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: December 3, 2024
    Assignees: Icahn School of Medicine at Mount Sinai, The Methodist Hospital
    Inventors: Shu-Hsia Chen, Ping-Ying Pan
  • Patent number: 12144865
    Abstract: The present invention relates to novel binder-prodrug conjugates (APDCs) where binders are conjugated with inactive precursor compounds of kinesin spindle protein inhibitors, and to antibody-drug conjugates ADCs and to processes for producing these APDCs and ADCs.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: November 19, 2024
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Leo Marx, Beatrix Stelte-Ludwig, Carsten Terjung, Christoph Mahlert, Simone Greven, Anette Sommer, Sandra Berndt